Actively Recruiting
A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
Led by Taisho Pharmaceutical Co., Ltd. · Updated on 2025-12-16
300
Participants Needed
1
Research Sites
86 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A clinical study to evaluate the long-term safety and efficacy of TS-172 in hyperphosphatemia patients on hemodialysis.
CONDITIONS
Official Title
A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Hyperphosphatemia patients with chronic kidney disease receiving hemodialysis 3 times a week for at least 12 weeks before the study
- Patients aged 18 years or older at the time of informed consent
- Patients prescribed at least one phosphate binder at a stable dose for at least 2 weeks before the study
- Serum phosphorus concentration between 3.5 mg/dL and 7.0 mg/dL at screening
You will not qualify if you...
- Patients with serum intact PTH concentration over 500 pg/mL at screening
- Patients who have had previous parathyroid treatments such as surgery or ethanol injection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Taisho Pharmaceutical Co., Ltd selected site
Tokyo, Japan
Actively Recruiting
Research Team
T
Taisho Pharmaceutical Co., Ltd.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here